TITLE

Antiepileptogenic Agents: How Close Are We?

AUTHOR(S)
Temkin, N.R.; Jarell, A.D.; Anderson, G.D.
PUB. DATE
June 2001
SOURCE
Drugs;Jun2001, Vol. 61 Issue 8, p1045
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Epilepsy is a common neurological condition, affecting about 4% of individuals over their lifetime. Epilepsy can be idiopathic, secondary to an underlying genetic abnormality or unknown causes, or acquired. Known potential causes account for about one third of epilepsy. Control of epilepsy has primarily focused on suppressing seizure activity after epilepsy has developed. An intriguing possibility is to control acquired epilepsy by preventing epileptogenesis, the process by which the brain becomes epileptic. Many laboratory models simulate human epilepsy as well as provide a system for studying epileptogenesis. The kindling model involves repeated application of subconvulsive electrical stimulation to the brain, leading to spontaneous seizures. Other models include the cortical or systemic injection of various chemicals. These models suggest that many antiepileptic drugs, from phenobarbital and valproate (valproic acid) to levetiracetam and tiagabine, have antiepileptogenic potential. Some promising other possibilities include N-methyl-D-aspartate (NMDA) or alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) antagonists as well as the neurotrophins and their receptors. Phenobarbital, phenytoin, valproate, carbamazepine and, to a very limited extent, diazepam have been evaluated in clinical trials to test whether they actually prevent epileptogenesis in humans. Results have been very disappointing. Meta-analyses of 12 different drug-condition combinations show none with significantly lower unprovoked seizure rates among those receiving the active drug. In 4 of the 12, the observed rate was actually slightly higher among treated individuals. None of the newer drugs have been evaluated in antiepileptogenesis trials. Until some drugs demonstrate a clear antiepileptogenic effect in clinical trials, the best course to reduce the incidence of epilepsy is primary prevention of the risk-increasing events — for example, wearing helmets, using seat belts, or decreasing the risk of stroke by reducing smoking.
ACCESSION #
4745478

 

Related Articles

  • Tough seizures: When the first anticonvulsant fails. Kossoff, Eric H. // Contemporary Pediatrics;Sep2002, Vol. 19 Issue 9, p85 

    Provides information on using anticonvulsant therapy for children with epilepsy. Consideration in the decision to use an anticonvulsant in an adolescent; Things that should be confirmed by a neurologist who is asked to evaluate a child with epilepsy after the first medication has failed;...

  • Anti-Epileptic Drugs for Pain #271. Hepner, Seth; Claxton, René // Journal of Palliative Medicine;Jul2013, Vol. 16 Issue 7, p799 

    The article reviews several antidepressant medicines which are used to treat neuropathy pain. Gabapentin is an effective drug in treatment of central and peripheral neuropathic pain with dose regulated for renal dysfunction. Pregabalin is an effective drug for treatment of diabetic neuropathic...

  • New treatment for partial epilepsy.  // British Journal of Hospital Medicine (17508460);Oct2012, Vol. 73 Issue 10, p549 

    The article reports that Perampanel (Fycompa) has been launched to treat uncontrolled partial epilepsy.

  • Antiepileptic drugs.  // Reactions Weekly;11/27/2010, Issue 1329, p9 

    The article describes the cases of 18 patients, eleven females and seven males, who developed skin rashes while undergoing treatment with antiepiletic drugs.

  • Reduction in polypharmacy for epilepsy. Shorvon, S.D.; Reynolds, E.H. // British Medical Journal;10/27/1979, Vol. 2 Issue 6197, p1023 

    Examines the use of anticonvulsant polypharmacy for the treatment of patients with chronic epilepsy. Measurement of blood drug concentration; Use of the drug for the control of seizures; Occurrence of chronic toxicity after the administration of polypharmacy.

  • Successful treatment of pharmacoresistent continuous spike wave activity during slow sleep with levetiracetam. Hoppen, Thomas; Sandrieser, Torsten; Rister, Manfred // European Journal of Pediatrics;2003, Vol. 162 Issue 1, p59 

    Investigates the efficacy of anti-epileptic drugs in patients with atypical benign partial epilepsy. Achievement of seizure control with different anti-epileptic drugs; Tolerance of therapy without serious side effects; Improvement of the behavior and intellectual function after introduction of...

  • The Use of Anticonvulsants in Neurological Conditions Other Than Epilepsy: A Review of the Evidence from Randomised Controlled Trials. Beghi, E. // CNS Drugs;1999, Vol. 11 Issue 1, p61 

    Anticonvulsant drugs are used in several neurological conditions in addition to epilepsy. However, only trigeminal neuralgia, diabetic neuropathy, migraine and essential tremor seem to benefit from treatment with selected anticonvulsants and other drug classes. Carbamazepine is the treatment of...

  • Central pain. Illis, L.S. // BMJ: British Medical Journal (International Edition);5/19/90, Vol. 300 Issue 6735, p1284 

    Focuses on the causes of central pain. Definition and mechanisms of central pain; Method to manage central pain; Utilization of anticonvulsant drugs in intractable pain.

  • Lacosamide: A novel antiepileptic drug. Tanzi, Maria G. // Pharmacy Today;Dec2008, Vol. 14 Issue 12, p31 

    The article evaluates the Vimpat lacosamide, an antiepileptic medication from UCB SA.

  • Management of childhood epilepsy.  // British Medical Journal;4/16/1977, Vol. 1 Issue 6067, p986 

    Investigates the management of children with epilepsy. Prescription of anticonvulsant drugs; Basis of drug treatment on the type of epilepsy; Assessment of treatment effectiveness and drug effects with the long term use of anticonvulsants.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics